Arvinas (ARVN) Enterprise Value (2017 - 2026)
Arvinas (ARVN) posted quarterly Enterprise Value of -$614.9 million for Q1 2026, up 35.57% year-over-year from -$453.6 million in Q1 2025, and up 10.29% quarter-over-quarter from -$685.4 million in Q4 2025.
Arvinas (ARVN) Enterprise Value (2017 - 2026) Analysis & Trends
Arvinas' Enterprise Value history runs 10 years deep, the most recent figure standing at -$614.9 million for Q1 2026.
- In Q1 2026, Enterprise Value rose 35.57% year-over-year to -$614.9 million; the TTM figure through Mar 2026 stood at -$614.9 million (up 35.57% YoY), while the FY2025 annual figure was -$685.4 million, up 34.06% from the prior year.
- Enterprise Value for Q1 2026 stood at -$614.9 million, up from -$685.4 million in the prior quarter.
- The five-year high for Enterprise Value was -$66.8 million in Q1 2022, with the low at -$1.2 billion in Q1 2024.
- The 5-year median for Enterprise Value is -$160.3 million (2024), against an average of -$436.2 million.
- The sharpest annual moves came in 2022 and 2025: Enterprise Value surged 91.06% in 2022, then sank 824.41% in 2025.
- Arvinas' Enterprise Value stood at -$86.8 million in 2022, then sank by 265.44% to -$317.2 million in 2023, then slumped by 227.68% to -$1.0 billion in 2024, then surged by 34.06% to -$685.4 million in 2025, then grew by 10.29% to -$614.9 million in 2026.
- Business Quant data shows ARVN's Enterprise Value at -$614.9 million in Q1 2026, -$685.4 million in Q4 2025, and -$787.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Arvinas | 585.74 Mn | 17.84 Mn | - | -567.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -567.90 Mn |
| Mar 31, 2026 | -614.90 Mn |
| Dec 31, 2025 | -685.40 Mn |
| Sep 30, 2025 | -787.60 Mn |
| Jun 30, 2025 | -861.20 Mn |
| Mar 31, 2025 | -954.30 Mn |
| Dec 31, 2024 | -1.04 Bn |
| Sep 30, 2024 | -85.20 Mn |
| Jun 30, 2024 | -160.30 Mn |
| Mar 31, 2024 | -1.17 Bn |
| Dec 31, 2023 | -317.20 Mn |
| Sep 30, 2023 | -119.20 Mn |
| Jun 30, 2023 | -96.10 Mn |
| Mar 31, 2023 | -135.70 Mn |
| Dec 31, 2022 | -86.80 Mn |
| Sep 30, 2022 | -138.10 Mn |
| Jun 30, 2022 | -97.70 Mn |
| Mar 31, 2022 | -66.80 Mn |
| Dec 31, 2021 | -112.80 Mn |
| Sep 30, 2021 | -1.54 Bn |